-
Innovation Ranking
NewInnovation Ranking – NGM Biopharmaceuticals Inc
NGM Biopharmaceuticals Inc (NGM Bio) operates as a clinical-stage bio pharmaceutical company that develops pipeline of biological therapeutics for the treatment of cardio-metabolic, immuno-oncology, retinal and liver diseases and ophthalmic diseases. The company’s pipeline products include NGM707, NGM831, NGM438, NGM120, NGM621, MK-3655 and Aldafermin. Its NGM707 is a novel dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript and NGM831 is the potential to fight tumors by shifting myeloid cells...
-
Product Insights
NewNet Present Value Model: NGM Biopharmaceuticals Inc’s NGM-120
Empower your strategies with our Net Present Value Model: NGM Biopharmaceuticals Inc's NGM-120 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NGM-707 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NGM-707 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NGM-707 in Ovarian Cancer Drug Details: NGM-707 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NGM-707 in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NGM-707 in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NGM-707 in Breast Cancer Drug Details: NGM-707 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NGM-707 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NGM-707 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NGM-707 in Non-Small Cell Lung Cancer Drug Details: NGM-707 is...
-
Company Insights
Innovation and Patenting activity of NGM Biopharmaceuticals Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of NGM Biopharmaceuticals Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NGM-395 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NGM-395 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NGM-395 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NGM-438 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NGM-438 in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NGM-438 in Melanoma Drug Details:NGM-438 is under development for the treatment of advanced solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NGM-707 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NGM-707 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NGM-707 in Solid Tumor Drug Details: NGM-707 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NGM-438 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NGM-438 in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NGM-438 in Prostate Cancer Drug Details:NGM-438 is under development for the treatment of...